MedTrace Logo

Intervention With a GABA Supplement in Prediabetics

NCT04303468 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2021-11-16

No results posted yet for this study

Summary

In this double-blind parallel placebo controlled intervention study the effects of 3 times daily 500 mg gamma-aminobutyric acid (GABA) supplementation on glucose tolerance and cardiovascular health will be assessed in prediabetics.

Conditions

Interventions

DIETARY_SUPPLEMENT

GABA

The dietary supplement GABA will be taken orally 3 times daily, before each main meal

OTHER

Placebo

Gelatin capsule containing powdered cellulose

Sponsors & Collaborators

  • Nunhems

    collaborator UNKNOWN

  • Agrico Research

    collaborator UNKNOWN

  • Avebe

    collaborator UNKNOWN

  • Wageningen University

    lead OTHER

Principal Investigators

  • Renger Witkamp, PhD · Wageningen University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-09-29
Primary Completion
2021-09-08
Completion
2021-09-08

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04303468 on ClinicalTrials.gov